Cumberland announces ifetroban NDA filing plan after shares plummet
Lesedauer weniger als 1 min
Die wichtigsten Punkte:
- After shares declined almost 49% in Monday's trading session, Cumberland Pharmaceuticals said it will file an NDA for cardiomyopathy associated with Duchenne muscular dystrophy candidate ifetroban.
- The company held a pre-NDA meeting with the US FDA recently and intends to use the phase 2 FIGHT DMD trial as the pivotal study, along with comparison data from two natural history databases.
- The study found that a high dose of ifetroban treatment led to a significant 5.4% absolute improvement in left ventricular ejection fraction (LVEF) compared to a control group that included placebo patients as well as propensity score-matched natural history patients.
- During a Type C meeting in January, the FDA suggested a phase 3 trial and had issues regarding the FIGHT DMD results, including the suitability of the LVEF endpoint, comparator-related questions, and the development of the statistical analysis plan. Cumberland responded with additional data, natural history data from a second DMD registry, and information on how it developed its statistical analysis plan.
- The oral drug's mechanism of action is by blocking the thromboxane receptor, which plays a key role in inflammation and fibrosis.
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.